Navigation Links
LipoScience Announces Appointment Of William Cromwell, M.D., As Chief Medical Officer
Date:9/6/2013

RALEIGH, N.C., Sept. 6, 2013 /PRNewswire/ -- LipoScience, Inc. (NASDAQ: LPDX), a diagnostic company pioneering a new field of personalized NMR diagnostics to advance the quality of patient care in cardiovascular, metabolic and other diseases, today announced the appointment of William Cromwell, M.D. as Chief Medical Officer.

"We are delighted to welcome Dr. William Cromwell back to LipoScience," said Bob Greczyn, interim chief executive officer, LipoScience, Inc. "Dr. Cromwell's achievements and expertise as an opinion leader in lipid and lipoprotein disorders make him an ideal addition to our team as we continue to grow as a leader in advancing the quality of patient care in cardiovascular, metabolic and other lipid-related diseases."

Dr. Cromwell is an internationally recognized expert in the management of lipid and lipoprotein disorders. In addition to being board certified by the American Board of Clinical Lipidology, Dr. Cromwell is a fellow of the American Heart Association Council on Atherosclerosis, Thrombosis and Vascular Biology, Fellow of the National Lipid Association and Fellow of the American Academy of Family Physicians.  He is also a member of the American Heart Association Council on Nutrition, Physical Activity, and Metabolism, as well as the Southeastern Lipid Association, and serves as Adjunct Associate Professor in the Hypertension and Vascular Disease Center at Wake Forest University School of Medicine. He joins LipoScience for a second time, having previously served as the company's Chief Medical Officer from 1999 – 2005.

Dr. Cromwell joins LipoScience from the Lipoprotein and Metabolic Disorders Institute (LMDI) in Raleigh, North Carolina, which he founded in 1998 as a center of excellence for the comprehensive evaluation and management of lipid (cholesterol and triglyceride) disorders affecting patients of all ages, as well as the evaluation of early vascular disease. He received his doctoral degree in medicine from the Louisiana State University School of Medicine in New Orleans, Louisiana. He has also published over 20 peer-reviewed book chapters, review articles, and original research in lipid and lipoprotein disorders.

About LipoScience  
LipoScience, Inc. is pioneering a new field of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. The company's first proprietary diagnostic test, the NMR LipoProfile® test, measures the number of low-density lipoprotein particles (LDL-P) in a blood sample and provides physicians and their patients with actionable information to personalize management of risk for heart disease. To date, over 10 million NMR LipoProfile tests have been ordered. LipoScience's automated clinical analyzer, Vantera®, has been cleared by the U.S. Food and Drug Administration (FDA). It requires no previous knowledge of NMR technology to operate and has been designed to dramatically simplify complex technology through ease of use and walk-away automation. The Vantera Clinical Analyzer will be placed with national and regional clinical laboratories.

LipoScience is driving NMR diagnostics toward becoming a clinical standard of care by decentralizing its technology and expanding its menu of personalized diagnostic tests to address a broad range of cardiovascular, metabolic and other diseases. For further information on LipoScience, please visit www.liposcience.com and www.theparticletest.com.

Forward-Looking Statements  
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. These forward-looking statements include statements about the Company's expectations for the future demand for its products and the factors that drive such demand. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Further information on potential factors and other risks that could affect the Company's business and operating results is included in the Company's Quarterly Report on Form 10-Q for the quarter ended July 31, 2013 and other filings the Company makes with the Securities and Exchange Commission from time to time.  These documents are available on the SEC Filings section of the Investor Relations page of the Company's website at http://investor.liposcience.com/. The statements made herein are based on information available to LipoScience as of the date of this press release, and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE LipoScience, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. LipoScience Announces Data Presented at the 2013 American Diabetes Association Meeting
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
4. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
5. Misonix Announces New Distribution Agreement For Panama
6. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
7. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
8. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
9. Soligenix Announces Further Progress with ThermoVax™ for Long-Term Vaccine ThermoStability
10. Masimo Announces New Low-Profile Infant and Neonatal Pulse Oximetry Sensors
11. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 AbbVie, a global ... Award-winning choreographer Julianne Hough is helping to ... in the Know about ME in EndoMEtriosis . " ... inspiring women to learn about and understand endometriosis, a ... and to address their symptoms with a healthcare ...
(Date:3/23/2017)... MONICA, Calif. , March 23, 2017   ... launch of a native mobile app for the iPhone. ... standard for surgery coordination and communication for physician offices, ... a native mobile app offers iPhone users even faster, ... "Casetabs is making it even easier to connect care ...
(Date:3/23/2017)... , March 23, 2017 The ... value of USD 25.7 billion by 2025, according to a ... expected to grow at a faster rate due to rising ... awareness about various types of esthetic procedures used for treating ... disorders. Hence, they are considered as the highest revenue generators ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... ... Disease Management Accreditation from the NCQA. The accreditation covers StayWell’s asthma, coronary artery ... Accredited status is granted to organizations that have excellent programs for the delivery ...
(Date:3/23/2017)... ... ... The TouchPoint Solution, home of Buzzies *, is boosting the Arizona ... “Buzzies change the way we interact with stress and live our day-to-day lives,” said ... in December 2016, The TouchPoint Solution has sold more than $750,000 in product sales. ...
(Date:3/23/2017)... City (PRWEB) , ... March 23, 2017 , ... After ... fall, FaceCradle , the most-funded travel pillow in crowdfunding history, has ... delivery of its wildly popular travel innovation to Americans. , “We’re excited to be ...
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, a ... of people’s health and nutrition, announced its product Leyzene is now available for ... develops nutritional supplements that help people improve all aspects of their health so ...
Breaking Medicine News(10 mins):